This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top- and bottom-line numbers, along with its pipeline progress, when it reports Q4 results.
Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
Repligen's (RGEN) beats on both earnings and revenues in Q4. However, stock declines.
Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Progress of its pipeline candidates is likely to have increased Moderna's (MRNA) operating expenses in the fourth quarter.
What Awaits Jazz Pharmaceuticals (JAZZ) in Q4 Earnings?
by Zacks Equity Research
Progress of its pipeline candidates and launch of Sunosi is likely to have increased Jazz Pharmaceuticals (JAZZ) operating expenses in the fourth quarter. Xyrem likely to have continued strong demand trend.
What Awaits Spectrum Pharmaceuticals (SPPI) in Q4 Earnings?
by Zacks Equity Research
Progress of its pipeline candidates is likely to have increased Spectrum Pharmaceuticals' (SPPI) operating expenses in the fourth quarter.
Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
Epizyme (EPZM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Epizyme (EPZM) to provide commercialization updates on its sarcoma drug when it releases fourth-quarter 2019 earnings.
Akorn (AKRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Akorn's (AKRX) fourth-quarter 2019 results are likely to reflect a decline in sales volume due to stiffening competition.
Is a Beat in the Cards for Clovis' (CLVS) Earnings in Q4?
by Zacks Equity Research
Clovis' (CLVS) sole marketed drug, Rubraca, is likely to have driven revenues in the fourth quarter.
What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings?
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) is likely to provide update on its commercialization plan for Caplyta, approved for treating schizophrenia in December 2019, on the Q4 call.
NewLink (NLNK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to updates on NewLink's (NLNK) merger with Lumos Pharma, when the former releases fourth-quarter 2019 results.
Acorda (ACOR) Q4 Earnings Top Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Acorda (ACOR) beat earnings and revenue estimates in the fourth quarter of 2019.
Agios' (AGIO) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Agios (AGIO) rides high on earnings and revenue beat in the fourth quarter of 2019.
Will Vericel Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Vericel.
The Zacks Analyst Blog Highlights: MarineMax, Metropolitan Bank, Earthstone Energy, Rite Aid and Vericel
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MarineMax, Metropolitan Bank, Earthstone Energy, Rite Aid and Vericel
The Zacks Analyst Blog Highlights: Accuray, MagnaChip Semiconductor, Rite Aid, Vericel and RGC Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Accuray, MagnaChip Semiconductor, Rite Aid, Vericel and RGC Resources
Small Business Optimism Rises Amid Coronavirus Fears: 5 Picks
by Nalak Das
The optimism regarding small businesses remains near an all-time high albeit a slowing U.S. economy.
Virus or No Virus, Investing Case in US Stocks Looks Solid!
by Tirthankar Chakraborty
U.S. stocks are heavily exposed to the domestic economy where data continues to improve. And even if skeptics worry about the virus outbreak, developed markets are more stable than emerging markets during chaotic times.
Radware (RDWR) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Radware (RDWR) delivered earnings and revenue surprises of -4.17% and -0.22%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Inovio Gets FDA Nod to Begin Study on INO-3107, Stock Gains
by Zacks Equity Research
The FDA accepts Inovio's (INO) IND application for INO-3107 to initiate a phase I/II study for the treatment of recurrent respiratory papillomatosis, a rare disease caused by HPV. Stock up.
What's in Store for Acorda (ACOR) This Earnings Season?
by Zacks Equity Research
During Acorda's (ACOR) Q4 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug Inbrija.
Vericel Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Vericel has been struggling lately, but the selling pressure may be coming to an end soon.
Stock Market News for Nov 6, 2019
by Zacks Equity Research
Wall Street made nominal progress on Nov 5, given the record highs major indexes reached on Monday.
Will Vericel (VCEL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Vericel (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Vericel (VCEL) a New Buy Stock
by Zacks Equity Research
Vericel (VCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.